NovoCure (NASDAQ:NVCR) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS

NovoCure (NASDAQ:NVCR) posted its quarterly earnings data on Thursday. The medical equipment provider reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.13), FiscalAI reports. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The firm had revenue of $174.06 million during the quarter, compared to analyst estimates of $167.77 million. During the same period in the prior year, the company posted ($0.31) earnings per share. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year.

Here are the key takeaways from NovoCure’s conference call:

• Strong commercial and financial start to 2026 — net revenue was $174 million (+12% YoY) with double?digit active patient growth, and the company raised full?year revenue guidance to $690M–$710M and updated Adjusted EBITDA guidance to -$15M to breakeven.
• Optune PAX FDA approval and U.S. launch showed early traction — in ~7 weeks the company certified 868 HCPs, received 169 prescriptions, completed 90 patient starts (83 patients on therapy at quarter end), and secured first major payer coverage for >30M lives.
• Clinical momentum in pancreatic cancer — PANOVA?4 met its primary endpoint (DCR 74% vs 48% historical) and PANOVA?3 results plus preclinical data (including potential synergy with KRAS inhibitors) support further combo development and metastatic program exploration.
• Q1 GAAP loss widened due to a one?time charge — net loss was $71M (vs $34M a year ago) largely from a $43M share?based compensation charge tied to Optune PAX approval; excluding that charge, net loss was $28M, with cash and investments of $432M at quarter end.

NovoCure Trading Up 27.5%

NASDAQ:NVCR traded up $3.28 during trading hours on Thursday, hitting $15.21. The company had a trading volume of 7,709,297 shares, compared to its average volume of 1,797,438. The company has a current ratio of 2.90, a quick ratio of 2.71 and a debt-to-equity ratio of 0.70. The company has a 50-day moving average of $12.03 and a 200 day moving average of $12.43. The company has a market cap of $1.76 billion, a P/E ratio of -12.47 and a beta of 0.82. NovoCure has a 1 year low of $9.82 and a 1 year high of $20.06.

Insider Buying and Selling

In other NovoCure news, CEO Frank X. Leonard sold 5,607 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total value of $74,629.17. Following the completion of the sale, the chief executive officer directly owned 493,793 shares in the company, valued at $6,572,384.83. This represents a 1.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman William F. Doyle sold 71,887 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $12.98, for a total value of $933,093.26. Following the completion of the sale, the chairman owned 328,397 shares of the company’s stock, valued at approximately $4,262,593.06. The trade was a 17.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 140,041 shares of company stock worth $1,860,116 over the last quarter. Corporate insiders own 5.52% of the company’s stock.

Institutional Trading of NovoCure

Several large investors have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC grew its holdings in NovoCure by 178.0% in the 4th quarter. Corient Private Wealth LLC now owns 97,368 shares of the medical equipment provider’s stock valued at $1,259,000 after buying an additional 62,341 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in NovoCure by 14.5% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider’s stock valued at $422,000 after buying an additional 4,124 shares in the last quarter. Empowered Funds LLC purchased a new position in shares of NovoCure during the 4th quarter worth $33,000. XTX Topco Ltd grew its holdings in shares of NovoCure by 159.2% during the 4th quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider’s stock worth $760,000 after purchasing an additional 36,111 shares during the period. Finally, Vestal Point Capital LP grew its holdings in shares of NovoCure by 31.3% during the 4th quarter. Vestal Point Capital LP now owns 525,000 shares of the medical equipment provider’s stock worth $6,788,000 after purchasing an additional 125,000 shares during the period. 84.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on NVCR shares. HC Wainwright increased their price objective on NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Evercore set a $20.00 price objective on NovoCure in a research note on Monday, January 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a research note on Tuesday, April 21st. Finally, Wedbush reissued a “neutral” rating and issued a $18.00 price objective on shares of NovoCure in a research note on Thursday, April 16th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $26.93.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.